Literature DB >> 32052321

Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression.

Clarissa Laczkovics1, Oswald D Kothgassner2, Anna Felnhofer3, Claudia M Klier3.   

Abstract

In this report, we present a case of a 16,9-year-old patient with multiple substance use disorder (cannabis, MDMA, cocaine, ecstacy), severe depression, social phobia and narcissistic personality disorder.We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants.CBD was a safe and well tolerated medication for this patient. Upon treatment with CBD and cessation of the antidepressant medication, the patient improved regarding depressive as well as anxiety symptoms including simple phobias and symptoms of paranoia and dissociation. Furthermore, the patient quit abusing illegal drugs including THC without showing withdrawal symptoms. This is the first report of CBD medication in a patient with multiple substance use disorder with a positive outcome.Until today it is not clear if CBD holds promise as a therapeutic option in substance use disorder as RCTs are lacking, but in this single case the substance seems to work in various domains.

Entities:  

Keywords:  Adolescent; Anxiety; Cannabidiol; Depression; Substance use disorder

Mesh:

Substances:

Year:  2020        PMID: 32052321      PMCID: PMC7954719          DOI: 10.1007/s40211-020-00334-0

Source DB:  PubMed          Journal:  Neuropsychiatr        ISSN: 0948-6259


  18 in total

1.  Cannabidiol in Anxiety and Sleep: A Large Case Series.

Authors:  Scott Shannon; Nicole Lewis; Heather Lee; Shannon Hughes
Journal:  Perm J       Date:  2019

2.  Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.

Authors:  Yasmin L Hurd; Sharron Spriggs; Julia Alishayev; Gary Winkel; Kristina Gurgov; Chris Kudrich; Anna M Oprescu; Edwin Salsitz
Journal:  Am J Psychiatry       Date:  2019-05-21       Impact factor: 18.112

Review 3.  Cannabidiol (CBD) use in psychiatric disorders: A systematic review.

Authors:  Stefania Bonaccorso; Angelo Ricciardi; Caroline Zangani; Stefania Chiappini; Fabrizio Schifano
Journal:  Neurotoxicology       Date:  2019-08-11       Impact factor: 4.294

4.  Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Authors:  Mateus M Bergamaschi; Regina Helena Costa Queiroz; Marcos Hortes Nisihara Chagas; Danielle Chaves Gomes de Oliveira; Bruno Spinosa De Martinis; Flávio Kapczinski; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio E Nardi; Rocio Martín-Santos; Jaime Eduardo Cecílio Hallak; Antonio Waldo Zuardi; José Alexandre S Crippa
Journal:  Neuropsychopharmacology       Date:  2011-02-09       Impact factor: 7.853

5.  Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

Authors:  David J Allsop; Jan Copeland; Nicholas Lintzeris; Adrian J Dunlop; Mark Montebello; Craig Sadler; Gonzalo R Rivas; Rohan M Holland; Peter Muhleisen; Melissa M Norberg; Jessica Booth; Iain S McGregor
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

6.  Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Authors:  Sagnik Bhattacharyya; Paul D Morrison; Paolo Fusar-Poli; Rocio Martin-Santos; Stefan Borgwardt; Toby Winton-Brown; Chiara Nosarti; Colin M O' Carroll; Marc Seal; Paul Allen; Mitul A Mehta; James M Stone; Nigel Tunstall; Vincent Giampietro; Shitij Kapur; Robin M Murray; Antonio W Zuardi; José A Crippa; Zerrin Atakan; Philip K McGuire
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

7.  Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report.

Authors:  Scott Shannon; Janet Opila-Lehman
Journal:  Integr Med (Encinitas)       Date:  2015-12

8.  Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.

Authors:  Sagnik Bhattacharyya; Robin Wilson; Elizabeth Appiah-Kusi; Aisling O'Neill; Michael Brammer; Jesus Perez; Robin Murray; Paul Allen; Matthijs G Bossong; Philip McGuire
Journal:  JAMA Psychiatry       Date:  2018-11-01       Impact factor: 21.596

9.  Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

Authors:  Jose M Trigo; Alexandra Soliman; Lena C Quilty; Benedikt Fischer; Jürgen Rehm; Peter Selby; Allan J Barnes; Marilyn A Huestis; Tony P George; David L Streiner; Gregory Staios; Bernard Le Foll
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

10.  Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

Authors:  Philip McGuire; Philip Robson; Wieslaw Jerzy Cubala; Daniel Vasile; Paul Dugald Morrison; Rachel Barron; Adam Taylor; Stephen Wright
Journal:  Am J Psychiatry       Date:  2017-12-15       Impact factor: 18.112

View more
  6 in total

1.  Long-Term Low-Dose Delta-9-Tetrahydrocannbinol (THC) Administration to Simian Immunodeficiency Virus (SIV) Infected Rhesus Macaques Stimulates the Release of Bioactive Blood Extracellular Vesicles (EVs) that Induce Divergent Structural Adaptations and Signaling Cues.

Authors:  Yuan Lyu; Steven Kopcho; Mahesh Mohan; Chioma M Okeoma
Journal:  Cells       Date:  2020-10-06       Impact factor: 6.600

2.  Optimizing Photoperiod Switch to Maximize Floral Biomass and Cannabinoid Yield in Cannabis sativa L.: A Meta-Analytic Quantile Regression Approach.

Authors:  Michelle Dang; Nishara Muthu Arachchige; Lesley G Campbell
Journal:  Front Plant Sci       Date:  2022-01-10       Impact factor: 5.753

Review 3.  Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression.

Authors:  Ines Gallego-Landin; Alba García-Baos; Adriana Castro-Zavala; Olga Valverde
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

Review 4.  Cannabidiol (CBD) in Cancer Management.

Authors:  Kylie O'Brien
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

5.  Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico.

Authors:  Flor Cristina Ortiz Rios; Itzel Guadalupe Dávila Ruiz; Elisa Sacal Dumani
Journal:  Drugs Context       Date:  2022-09-19

Review 6.  Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders?

Authors:  Saoirse E O'Sullivan; Carl W Stevenson; Steven R Laviolette
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.